References:1.Germain DP., et al. Fabry disease. Orphanet Journal of Rare Diseases 2010, 5:30.
2.Ortiz A, et al. Fabry disease revisited: management and treatment recommendations for adult patients Mol Genet Metab. 2018; 123:416-27.
3.Weidemann F., et al. Long-term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome With Early Treatment Circulation. 2009 Feb 3;119(4):524-9.
4.Germain DP et al Ten-year Outcome of Enzyme Replacement Therapy With Agalsidase Beta in Patients With Fabry Disease J Med Genet 2015;52:353–3585.
5.https://data.health.gov.il/Drugs/index.html#!/medDetails/124%2094%2030313%2000 -Accessed at September 29th 2020.
6.Banikazemi et al. Agalsidase-beta Therapy for Advanced Fabry Disease: A Randomized Trial
Ann Intern Med. 2007 Jan 16;146(2):77-86.
7.Fabrazyme IL prescribing information as approved/ updated in accordance with the instructions of the Ministry of Health
8.Germain DP et al. Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase Beta Therapy in Patients With Fabry Disease. J Am Soc Nephrol 2007 May 18:(5):1547-1557.
9.Tondel et al. Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease J Am Soc Nephrol 2013 24:137-148
* Fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. (alfa - galactosidase A deficiency).
יש לעיין בעלון לרופא המעודכן כפי שאושר בהתאם להוראות משה" ב
